Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2013

01-06-2013 | Research Article

Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma

Authors: Leiguang Ye, Songlei Guan, Cong Zhang, Kuang-Hui Lee, Shilong Sun, Jun Wei, Baogang Liu

Published in: Tumor Biology | Issue 3/2013

Login to get access

Abstract

The present study was undertaken to develop a relatively quantitative enzyme-linked immunosorbent assay (ELISA) in-house using human leukocyte antigen class II-restricted epitopes in order to test circulating autoantibodies to human forkhead/winged helix transcription factor (FOXP3) as a biomarker for esophageal cancer. A total of 97 patients with esophageal squamous cell carcinoma (ESCC) and 227 healthy subjects were recruited for this study, and their plasma samples were collected for antibody analysis with the ELISA approach. Student’s t test showed that the anti-FOXP3 IgG antibody levels were significantly higher in the patient group than the control group (t = 6.23, P < 0.0001). Based on a cutoff value determined by the mean + 3SD of control IgG levels, the positive rate was 5.15 % in patients with ESCC as compared to 0.88 % in control subjects (X 2 = 6.53, P = 0.019, OR = 5.85, 95 % CI 1.12–30.67), in which patients at stage I had the highest positivity (11.54 %, X 2 = 12.15, P = 0.0005, OR = 13.10, 95 % CI 2.09–82.04). The sensitivity against >95 % specificity was 22.7 % for the IgG assay with an inter-assay deviation of 13.35 %. This work suggests that circulating IgG autoantibody to FOXP3 may be a potential biomarker for early diagnosis of esophageal cancer.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
3.
Lam KY, Ma L. Pathology of esophageal cancers: local experience and current insights. Chin Med J (Eng). 1997;10:459–64.
4.
Almhanna K, Strosberg JR. Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol. 2012;18:5679–87.PubMedCrossRef
5.
Coffer PJ, Burgering BMT. Forkhead-box transcription factors and their role in the immune system. Nat Rev. 2004;4:889–99.CrossRef
6.
Redpath M, Xu B, van Kempen LC, Spatz A. The dual role of the X-linked FoxP3 gene in human cancers. Mol Oncol. 2011;5:156–63.PubMedCrossRef
7.
Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R, Wejksza K, et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4+ T cells to T-regulatory cells. Cancer Res. 2011;71:3505–15.PubMedCrossRef
8.
Xu T, Duan Q, Wang G, Hu B. CD4 + CD25high regulatory T cell numbers and FOXP3 mRNA expression in patients with advanced esophageal cancer before and after chemotherapy. Cell Biochem Biophys. 2011;61:389–92.PubMedCrossRef
9.
Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grüssel S, Sipos B, et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism ofimmune evasion in cancer. Cancer Res. 2007;67:8344–50.PubMedCrossRef
10.
Ebert LM, Tan BS, Browning J, Svobodova S, Russell SE, Kirkpatrick N, et al. The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res. 2008;68:3001–9.PubMedCrossRef
11.
Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, Kerenidi T, et al. Foxp3 expression in human cancer cells. J Transl Med. 2008;6:19.PubMedCrossRef
12.
Cunha LL, Morari EC, Nonogaki S, Soares FA, Vassallo J, Ward LS. Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas. Clinics (São Paulo, Brazil). 2012;67:483–8.CrossRef
13.
Triulzi T, Tagliabue E, Balsari A, Casalini P. FOXP3 expression in tumor cells and implications for cancer progression. J Cell Physiol. 2013;228:30–5.PubMedCrossRef
14.
Yoshii M, Tanaka H, Ohira M, Muguruma K, Iwauchi T, Lee T, et al. Expression of Forkhead box P3 in tumour cells causes immunoregulatory function of signet ring cell carcinoma of the stomach. Br J Cancer. 2012;106:1668–74.PubMedCrossRef
15.
Söllner J, Heinzel A, Summer G, Fechete R, Stipkovits L, Szathmary S, et al. Concept and application of a computational vaccinology workflow. Immunome Res. 2010;6 Suppl 2:S7.PubMedCrossRef
16.
Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinforma. 2010;11:568.CrossRef
17.
Liu L, Liu N, Liu B, Yang Y, Zhang Q, Zhang W, et al. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer? J Cancer Res Clin Oncol. 2012;138:1737–42.PubMedCrossRef
18.
Guan S, Liu B, Zhang C, Lee K-H, Sun S, Wei J. Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma. Clin Transl Oncol. 2013. doi:10.​1007/​s12094-013-1007-3.
19.
Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol. 2007;18:868–73.PubMedCrossRef
20.
Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009;276:6880–904.PubMedCrossRef
21.
Lam S, Boyle P, Healey GF, Maddison P, Peek L, Murray A, et al. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila). 2011;4:1126–34.CrossRef
22.
Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol. 2012;33:1319–26.PubMedCrossRef
23.
Ranju R, Arora S, Chattopadhyay TK, Shukla NK, Mathur M. Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int J Cancer. 2000;86:791–5.
24.
Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000;89:1677–83.PubMedCrossRef
25.
Fujita Y, Nakanishi T, Hiramatsu M, Mabuchi H, Miyamoto Y, Miyamoto A, et al. Proteomics based approach identifying autoantibody against Peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res. 2006;12:6415–20.PubMedCrossRef
26.
Fujita Y, Nakanishi T, Miyamoto Y, Hiramatsu M, Mabuchi H, Miyamoto A, et al. Protemics based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett. 2008;263:280–90.PubMedCrossRef
27.
Dong J, Zeng B-H, Xu L-H, Wang J-Y, Li M-Z, Zeng M-S, et al. Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma. J Transl Med. 2010;8:81.PubMedCrossRef
28.
Zhou J-H, Zhang B, Kernstine KH, Zhong L. Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma. World J Gastroenterol. 2011;17:1373–8.PubMedCrossRef
Metadata
Title
Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma
Authors
Leiguang Ye
Songlei Guan
Cong Zhang
Kuang-Hui Lee
Shilong Sun
Jun Wei
Baogang Liu
Publication date
01-06-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0729-8

Other articles of this Issue 3/2013

Tumor Biology 3/2013 Go to the issue

Research Article

Lack of association between XRCC3 rs861539 (C > T) polymorphism and lung cancer risks: an update meta-analysis

Research Article

Apoptin induces apoptosis in nude mice allograft model of human bladder cancer by altering multiple bladder tumor-associated gene expression profiles

Research Article

Toll-like receptor 3 genetic variants and susceptibility to hepatocellular carcinoma and HBV-related hepatocellular carcinoma

Research Article

GSTT1 null genotype contributes to increased risk of gastric cancer in Chinese population: evidence from a meta-analysis

Research Article

PKCα is involved in the progression of kidney carcinoma through regulating netrin-1/UNC5B signaling pathway

Review

Colorectal cancer: a researcher’s perspective of the molecular angel’s gone eccentric in the Vale of Kashmir
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits